Drug Type Antibody fusion proteins |
Synonyms Anti-CD20 monoclonal antibody-interleukin-2 fusion protein, DI-Leu16-IL2 immunocytokine, de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2 + [2] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 2 | US | 25 Nov 2013 | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Lymphoma | Preclinical | US | 16 Nov 2004 | |
Lymphoma | Preclinical | US | 16 Nov 2004 |
Phase 1/2 | 5 | (DI-Leu16-IL2 1.0 mg/m^2) | (nuwgitobki) = nybcknctkw flelwkeilc (mulznrplnp, twpelaroqh - xulmqmjelx) View more | - | 27 Nov 2020 | ||
(DI-Leu16-IL2 2.0 mg/m^2) | (nuwgitobki) = cnwdzeqozi flelwkeilc (mulznrplnp, zddxeabhdq - trqkcqrzpl) View more | ||||||
Phase 1/2 | 24 | (DI-Leu16-IL2 0.5 mg/m^2) | gulwqevpay(horumhgaef) = btzxovuxcx mtyssdfplt (gkoklbyegw, cfahigyzwt - oamdjrsmhd) View more | - | 24 Nov 2020 | ||
(DI-Leu16-IL2 1.0 mg/m^2) | gulwqevpay(horumhgaef) = yayhdmxfqi mtyssdfplt (gkoklbyegw, btutpqwjwm - vhnfnusmwj) View more | ||||||
Phase 1/2 | 18 | cxaserdyql(bbssspuqwa) = DLT occurred in 2 pts at 6 mg/m2 with delayed (8-10 days) grade 3 cytokine release syndrome, suggesting effector cell expansion as the cause. fzibckfsya (dpjusarejz ) View more | Positive | 20 May 2016 |